ULURU Inc. Announces First Shipment Of Altrazeal® To The Czech
Republic, Slovakia And South African Marketing Partners
ADDISON, Texas, Oct. 2, 2013 /PRNewswire/ -- ULURU Inc.
(OTCQB: ULUR), today announced it has completed the first shipments
of Altrazeal® to the Czech
Republic/Slovakia and South
African marketing partners.
Commenting on the initial shipments, Helmut Kerschbaumer, Managing Director of
Altrazeal GmbH, stated, "Extensive work has been conducted
preparing for the launch of Altrazeal® in these markets,
including participation at wound care conferences, conducting
clinical case studies and training wound care professionals and our
marketing partners. We are confident that our marketing partners
are well positioned to establish Altrazeal® as a major
competitor in the advanced wound care market. We are looking
forward to launching Altrazeal® in additional markets in
the fourth quarter 2013."
Altrazeal® is a scientifically engineered advanced
wound dressing designed to incorporate the desired features and
benefits of the ideal wound dressing. Altrazeal®
competes in the advanced wound dressing market which, worldwide, is
estimated to be $6.5 billion growing
annually at 13%. Altrazeal® has demonstrated potential
clinical and economic advantages in a number of chronic and acute
wounds including diabetic foot ulcers, venous leg ulcers and
geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on
the development of a portfolio of wound management and oral care
products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative
Nanoflex® Aggregate technology and OraDisc™ transmucosal
delivery system. For further information about ULURU Inc.,
please visit our website at www.ULURUinc.com. For further
information about Altrazeal®, please visit
www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to
numerous risks and uncertainties, including but not limited to the
launch of Altrazeal® in the territory, the
commercial potential of Altrazeal®, the establishment of
Altrazeal® as a major competitor and the demonstration
of cost savings and clinical benefits, and the risk factors
detailed in the Company's Annual Report on Form 10-K for the year
ended December 31, 2012, and other
reports filed by us with the Securities and Exchange
Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.